These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23438304)

  • 1. Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study.
    Nørgaard K; Scaramuzza A; Bratina N; Lalić NM; Jarosz-Chobot P; Kocsis G; Jasinskiene E; De Block C; Carrette O; Castañeda J; Cohen O;
    Diabetes Technol Ther; 2013 Apr; 15(4):273-80. PubMed ID: 23438304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
    Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
    Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
    Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M
    Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.
    Buse JB; Kudva YC; Battelino T; Davis SN; Shin J; Welsh JB
    Diabetes Technol Ther; 2012 Jul; 14(7):644-7. PubMed ID: 22524549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.
    Yeh HC; Brown TT; Maruthur N; Ranasinghe P; Berger Z; Suh YD; Wilson LM; Haberl EB; Brick J; Bass EB; Golden SH
    Ann Intern Med; 2012 Sep; 157(5):336-47. PubMed ID: 22777524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.
    Raccah D; Sulmont V; Reznik Y; Guerci B; Renard E; Hanaire H; Jeandidier N; Nicolino M
    Diabetes Care; 2009 Dec; 32(12):2245-50. PubMed ID: 19767384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.
    Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O
    Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study.
    Šoupal J; Petruželková L; Flekač M; Pelcl T; Matoulek M; Daňková M; Škrha J; Svačina Š; Prázný M
    Diabetes Technol Ther; 2016 Sep; 18(9):532-8. PubMed ID: 27482825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study.
    Picard S; Hanaire H; Baillot-Rudoni S; Gilbert-Bonnemaison E; Not D; Reznik Y; Guerci B
    Diabetes Technol Ther; 2016 Mar; 18(3):127-35. PubMed ID: 26950530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study.
    Slover RH; Welsh JB; Criego A; Weinzimer SA; Willi SM; Wood MA; Tamborlane WV
    Pediatr Diabetes; 2012 Feb; 13(1):6-11. PubMed ID: 21722284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic control after years of completing a clinical trial on sensor-augmented pump therapy.
    Quirós C; Giménez M; Orois A; Conget I
    Endocrinol Nutr; 2015 Nov; 62(9):447-50. PubMed ID: 26521155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.
    Hirsch IB; Abelseth J; Bode BW; Fischer JS; Kaufman FR; Mastrototaro J; Parkin CG; Wolpert HA; Buckingham BA
    Diabetes Technol Ther; 2008 Oct; 10(5):377-83. PubMed ID: 18715214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous glucose monitoring systems for type 1 diabetes mellitus.
    Langendam M; Luijf YM; Hooft L; Devries JH; Mudde AH; Scholten RJ
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD008101. PubMed ID: 22258980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensor-augmented pump therapy in very young children with type 1 diabetes: an efficacy and feasibility observational study.
    Frontino G; Bonfanti R; Scaramuzza A; Rabbone I; Meschi F; Rigamonti A; Battaglino R; Favalli V; Bonura C; Sicignano S; Gioia E; Zuccotti GV; Cerutti F; Chiumello G
    Diabetes Technol Ther; 2012 Sep; 14(9):762-4. PubMed ID: 22694194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.
    Hermanides J; Nørgaard K; Bruttomesso D; Mathieu C; Frid A; Dayan CM; Diem P; Fermon C; Wentholt IM; Hoekstra JB; DeVries JH
    Diabet Med; 2011 Oct; 28(10):1158-67. PubMed ID: 21294770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Cosentino C; Monami M; Mannucci E; Pala L
    Acta Diabetol; 2021 Apr; 58(4):401-410. PubMed ID: 32789691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous Subcutaneous Insulin Infusion in Adult Type 1 Diabetes Mellitus Patients: Results from a Public Health System.
    Moreno-Fernandez J; Gomez FJ; Pinés P; González J; López J; López LM; Blanco B; Roa C; Herranz S; Muñoz-Rodríguez JR
    Diabetes Technol Ther; 2019 Aug; 21(8):440-447. PubMed ID: 31199682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.